alexa Synergetic Effect Of PI3K Inhibition And Bcl2/STAT5 Knockdown In Breast Cancer Cell Lines | 22361
ISSN: 2157-7633

Journal of Stem Cell Research & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference and Exhibition on Cell & Gene Therapy

Daniel Diaz, Al?běta Filipov?, Hana Hreb?kov?, Rishikaysh Pisal, Kapil Chauhan, Wasay Mohiuddin, Jaroslav Mokry and Stanislav Filip
Posters: J Stem Cell Res Ther
DOI: 10.4172/2157-7633.S1.008
Abstract
PI3K signaling cascade is often hyperactivated in human cancer and is involved in both vertical and horizontal resistance to different targeted therapies. Inhibition of PI3K often show limited efficacy due to the reactivation of PI3K/AKT signaling. Kinases of the Janus family (JAKs) and their effector molecules (STATs) also play an important role in cancer since they are capable of stimulating cell proliferation, differentiation, migration, and survival. This pathway is activated upon binding of hormones and cytokines which are secreted by cancer cells and by cells from the tumor microenvironment. JAK2 is a known activator of PI3K and it is possible that JAK2 activation induced by PI3K inhibition contributes to AKT reactivation. Analyses of cytokine profiles after PI3K inhibition resulted in expression changes of several cytokines, IL-8 upregulation. Secreted IL-8 activates JAK2/STAT5 in breast cancer cells with a higher expression of CXCR receptors. It has been previously reported that activation of BIM and downregulation MCL1 are required for induction of cell death. The PI3K and JAK2 pathways activate the pro-survival protein MCL1 and suppress the pro-apoptotic protein BIM. Combined inhibition of PI3K/mTOR and JAK2 activates BIM and concomitantly downregulates MCL1, causing an increase in apoptosis, reduced tumor seeding and metastasis. Bcl-2 may serve as a target in the treatment of breast cancer as it is a known anti-apoptotic protein. Previous reports suggest that NF-kB and PI3K may contribute to Bcl-2 up-regulation in resistant cancers. Thus, IKK and PI3K inhibitors may potentially be used therapeutically in resistant breast cancers that have increased expression of Bcl-2. We propose that the knockdown of resistance molecules STAT5 and Bcl2 along with the chemical inhibition of PI3K will have a synergetic effect promoting an increased apoptotic rate of the treated breast cancer cells than by inhibiting only PI3K and JAK2.
Biography
Daniel D?az obtained his Biology BSc at the Universidad Ju?rez del Estado de Durango (M?xico), he then obtained his PhD diploma at the Universidad Aut?noma de Nuevo Le?n where he was awarded with an Academic Excellence fellowship from the National Board for Science and Technology (CONACyT) and a fellowship granted by the Science and Technology Research Support Program (PAICyT). He had the opportunity of undergoing extensive training in the Medical Center (Houston, TX) under the tutelage of several researchers in the University of Texas and M.D. Anderson Cancer Center and in the Institute of Biotechnology in Madrid, Spain. Currently, he is a Post-Doctoral Fellow in the Faculty of Medicine of the Charles University at Prague, Czech Republic.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7